CliffBio
small molecule

STEGLUJAN

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

Loss of exclusivityDecember 2031latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameSTEGLUJAN
Active ingredientERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE
Strength15MG;EQ 100MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2017
Marketing statusRX

Listed patents

PatentExpiresType
8080580December 2031substance, product
9439901October 2030use U-2214
9308204October 2030product
7326708*PEDMay 2027—
7326708November 2026substance, product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

STEGLUJAN patent cliff — loss of exclusivity December 2031 | CliffBio